中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
19期
8745-8749
,共5页
丹参酮%丹参酮Ⅱa磺酸钠%肝硬化%大鼠,Sprague-Dawley%Bcl-2%bcl-2相关X蛋白质
丹參酮%丹參酮Ⅱa磺痠鈉%肝硬化%大鼠,Sprague-Dawley%Bcl-2%bcl-2相關X蛋白質
단삼동%단삼동Ⅱa광산납%간경화%대서,Sprague-Dawley%Bcl-2%bcl-2상관X단백질
TANSHINONE%Sodium tanshinonⅡ asilate%Liver cirrhosis%Rats,Sprague-Dawley%Bcl-2%bcl-2-associated X protein
目的：观察丹参酮Ⅱa磺酸钠的抗肝纤维化作用。方法将48只SD大鼠随机分为正常对照组、模型组、低剂量给药组、高剂量给药组。通过50% CCl4/花生油溶液（1 ml/kg）灌胃诱导建立肝纤维化模型。低剂量组在建模同时每天腹腔注射丹参Ⅱa 磺酸钠注射液5 ml/kg，高剂量组在建模同时每天腹腔注射丹参Ⅱa磺酸钠注射液15 ml/kg。6周后观察大鼠肝脏大体形态、肝脏重量/体重比；运用HE和Masson染色检测肝纤维化的变化；全自动生化分析仪检测大鼠血清总胆红素（TBIL）、谷丙转氨酶（ALT）及谷草转氨酶（AST）的含量；Western blot检测肝脏组织中Bcl-2和Bax蛋白的表达。结果与模型组相比，丹参酮Ⅱa磺酸钠能够改善肝纤维化大鼠肝脏病理组织学结构，降低血清中TBIL、ALT、AST表达（P＜0.01）。与模型组相比，丹参酮Ⅱa磺酸钠给药组上调大鼠肝脏组织中Bcl-2蛋白的表达，下调Bax蛋白表达（P＜0.01）。结论丹参酮Ⅱa磺酸钠可能是通过调节Bcl-2和Bax蛋白的表达发挥抗肝纤维化的作用。
目的：觀察丹參酮Ⅱa磺痠鈉的抗肝纖維化作用。方法將48隻SD大鼠隨機分為正常對照組、模型組、低劑量給藥組、高劑量給藥組。通過50% CCl4/花生油溶液（1 ml/kg）灌胃誘導建立肝纖維化模型。低劑量組在建模同時每天腹腔註射丹參Ⅱa 磺痠鈉註射液5 ml/kg，高劑量組在建模同時每天腹腔註射丹參Ⅱa磺痠鈉註射液15 ml/kg。6週後觀察大鼠肝髒大體形態、肝髒重量/體重比；運用HE和Masson染色檢測肝纖維化的變化；全自動生化分析儀檢測大鼠血清總膽紅素（TBIL）、穀丙轉氨酶（ALT）及穀草轉氨酶（AST）的含量；Western blot檢測肝髒組織中Bcl-2和Bax蛋白的錶達。結果與模型組相比，丹參酮Ⅱa磺痠鈉能夠改善肝纖維化大鼠肝髒病理組織學結構，降低血清中TBIL、ALT、AST錶達（P＜0.01）。與模型組相比，丹參酮Ⅱa磺痠鈉給藥組上調大鼠肝髒組織中Bcl-2蛋白的錶達，下調Bax蛋白錶達（P＜0.01）。結論丹參酮Ⅱa磺痠鈉可能是通過調節Bcl-2和Bax蛋白的錶達髮揮抗肝纖維化的作用。
목적：관찰단삼동Ⅱa광산납적항간섬유화작용。방법장48지SD대서수궤분위정상대조조、모형조、저제량급약조、고제량급약조。통과50% CCl4/화생유용액（1 ml/kg）관위유도건립간섬유화모형。저제량조재건모동시매천복강주사단삼Ⅱa 광산납주사액5 ml/kg，고제량조재건모동시매천복강주사단삼Ⅱa광산납주사액15 ml/kg。6주후관찰대서간장대체형태、간장중량/체중비；운용HE화Masson염색검측간섬유화적변화；전자동생화분석의검측대서혈청총담홍소（TBIL）、곡병전안매（ALT）급곡초전안매（AST）적함량；Western blot검측간장조직중Bcl-2화Bax단백적표체。결과여모형조상비，단삼동Ⅱa광산납능구개선간섬유화대서간장병리조직학결구，강저혈청중TBIL、ALT、AST표체（P＜0.01）。여모형조상비，단삼동Ⅱa광산납급약조상조대서간장조직중Bcl-2단백적표체，하조Bax단백표체（P＜0.01）。결론단삼동Ⅱa광산납가능시통과조절Bcl-2화Bax단백적표체발휘항간섬유화적작용。
Objective To investigate the protective effects of Sodium Tanshinon Ⅱ Asilate on CCl4-induced hepatic fibrosis. Methods 48 SD rats were randomly divided into control group, model group, high-dose group, low-dose group. Apart from the control group, the rats in other three groups were administered with 50%CCl4 (1 ml/kg) for induction of hepatic fibrosis. The rats in the high-dose group (15 ml/kg) were intraperitoneal injected additionally with Sulfotanshinone Sodium Injection once every day. The rats in the low-dose group (5 ml/kg) were intraperitoneal injected additionally with Sulfotanshinone Sodium Injection once every day. After 6 weeks, macroscopic features of the liver and weight ratio of liver to body were measured. Liver fibrosis of the rats was evaluated by HE and Masson's trichrome staining. Activities of serum TBIL, ALT and AST were checked with automated biochemistry analyzer. The expression of Bcl-2 and Bax was detected by western blot. Results Compared with the model group, the pathologic manifestations improved and the activities of serum TBIL, ALT, AST in the high-dose group (P<0.01) and the low-dose group (P<0.01). The expression of Bcl-2 was up-regulated and the expression of Bax was down-regulated in the high-dose group (P<0.01) and the low-dose group (P<0.01). Conclusion Sodium TanshinonⅡ Asilate can prevent the progression of liver fibrosis possibly by regulating the expression of Bcl-2 and Bax.
